ObjectiveTo explore the clinical effect of Ningxin Huoxue Qutan decoction in the adjuvant treatment of angina pectoris after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS), and its effects on serum von Willebrand factor (vWF) and P-selectin (CD62p) levels. MethodsA total of 84 ACS patients who were treated in our hospital from February 2018 to February 2020 were selected, and they were divided into two groups by the random number table method, with 42 cases in each group. Patients in the control group were treated with PCI and conventional treatment, based on which patients in the experimental group were additionally treated with Ningxin Huoxue Qutan decoction as the adjuvant treatment, for a two-month treatment course. The clinical efficacy, the serum levels of vWF, CD62p and glycoprotein (GP) Ⅱb/Ⅲa receptor complex before and after treatment were compared between the two groups. ResultsThe total effective rate of treatment in the experimental group (90.48%) was significantly higher than that in the control group (71.43%), and the difference was statistically significant (P＜0.05). There were no statistically significant differences in the levels of serum vWF, P-selectin CD62p, GP Ⅱb/Ⅲa receptor complex between the two groups before treatment (P＞0.05). The serum CD62p, vWF, and GPⅡb/Ⅲa receptor complex levels of the experimental group were significantly lower than those of the control group after 2 months of treatment, and the differences were statistically significant (P＜0.05). There were no obvious abnormalities in liver and kidney function, urine routine and blood routine of the two groups, and no obvious adverse reactions occurred during the treatment. ConclusionThe adjuvant treatment of Ningxin Huoxue Qutan decoction can effectively improve the angina pectoris of ACS patients after PCI, improve the function of vascular endothelial cells and platelet activity in patients. And thus it is highly safe for treatment.

无